Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines

CROs look to buttress research models businesses with CRISPR/Cas tech

As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’ research models.

Quintiles maintains 'outperform' rating following recent flurry of activity

A recent spate of activity - including the acquisition of a Japanese CRO and a secondary equity offering - has boosted Quintiles’ investment appeal, an analyst says.

EMA re-confirms drug suspensions due to faulty trial data from GVK Biosciences

Following a re-examination requested by MAHs (marketing authorisation holders) for seven of the medicines suspended, the EMA has re-confirmed its recommendation to suspend hundreds of drugs following issues with clinical studies conducted at CRO GVK Biosciences in Hyderabad, India. 

House introduces companion bill to offer CROs a share of R&D tax credit

In a House bill that largely mirrors one reintroduced earlier this year in the Senate, CROs (contract research organizations) would be able to capture a share of the R&D tax credit, thereby making the US more competitive with other countries that offer such credits.

WuXi adding ADC tech to services in Ambrx acquisition

A consortium including WuXi PharmaTech has agreed to acquire biotech client Ambrx for its antibody-drug conjugate (ADC) conjugation technology.

inVentiv expands NIS services to help stem confusion on new EU trials regulation

inVentiv Health has expanded its compliance products and services to assist biopharma companies conducting non-interventional studies (NIS). 

Key Industry Events


Access all events listing

Our events, Shows & Conferences...